The mRNA flu vaccine has arrived. This week the Food and Drug Administration approved the first one, Moderna’s mFlusiva, for adults aged 50 and older, marking a significant technological shift in how seasonal influenza is fought.

Public health experts welcomed the decision, calling it a win at a moment when scepticism toward vaccines is growing. Whether patients will actually be able to get the shot this season is a separate question, and the early answer is complicated.

How mRNA Vaccines Differ

The distinction between mRNA shots and traditional vaccines comes down to what gets injected.

Dr. Amesh Adalja, an infectious disease specialist in Pittsburgh and senior scholar at the Johns Hopkins Center for Health Security, explained that mRNA vaccines deliver genetic instructions telling the body to manufacture a protein. That protein then prompts the immune system to generate antibodies capable of fighting the virus.

Conventional vaccines take a different route, typically containing a weakened version of the virus itself so the immune system can practice its response before encountering a real infection.

The technology is best known from the covid-19 era, when Pfizer and Moderna both used it. Moderna subsequently developed an mRNA vaccine for respiratory syncytial virus.

Its scientific foundation earned formal recognition in 2023, when Katalin Karikó and Drew Weissman received the Nobel Prize in physiology or medicine for the mRNA research that made those covid vaccines possible.

Speed Is the Real Advantage

The most consequential benefit is how quickly these vaccines can be produced.

Traditional flu vaccine manufacturing requires growing the virus, a slow biological process that dictates the entire production calendar. Removing that step compresses everything.

Adalja said the approval could cut the roughly six-month lead time for conventional flu vaccines roughly in half.

That creates a second advantage that matters enormously in flu seasons. If a dominant strain emerges later in the year that differs from what forecasters predicted, manufacturers can pivot rather than being locked into a formulation chosen months earlier.

Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor University and a prominent vaccine advocate, called that a significant advancement. He was more cautious about whether mRNA shots will eventually replace traditional flu vaccines, describing that as still an open question.

Pharmacies Are Split

Moderna has said it hopes to distribute mFlusiva during this flu season. Two major pharmacy chains have indicated they will not carry it.

Giant Eagle, recently acquired by Kroger pending regulatory approval, confirmed it will not offer the new shot. Spokeswoman Jannah Drexler said the chain would consider adding it if patient demand proves strong. She noted the company typically finalises its vaccine plans earlier in the year.

CVS, the largest pharmacy chain in the country, gave a similar response. Spokeswoman Roslyn Guarino said the company already holds ample supply for the 2026-27 season, including traditional and senior dose formulations, and will continue evaluating Moderna’s product as it does with all offerings.

Neither company explained why the new vaccine was excluded.

Smaller operators are moving differently. Wilson’s Pharmacy, a family-owned drugstore in Pittsburgh’s Lawrenceville neighbourhood, expects to have mFlusiva in stock by September, according to pharmacy technician Elizabeth Quinn.

A Difficult Regulatory Path

The approval came despite notable resistance at the federal level.

Health and Human Services Secretary Robert F. Kennedy Jr. has criticised mRNA technology repeatedly. Last August he cancelled $500 million in mRNA vaccine research, stating that the technology poses more risks than benefits for respiratory viruses.

That position draws sharp disagreement from most medical experts. Dr. Paul Offit, director of the Vaccine Education Center and a physician at Children’s Hospital of Philadelphia, called it a cruel joke played on the American people and advised the public to disregard it.

The FDA itself initially declined to review mFlusiva earlier this year, citing a dispute over testing methodology. The agency reversed that position quickly after Moderna made the decision public and criticism followed, according to reporting by The New York Times.

In June, an independent advisory committee voted unanimously to recommend approval, concluding the benefits appeared to outweigh the risks.

The FDA told TribLive its approach has been consistent, saying each application is evaluated on its own merits against established scientific and regulatory standards. Approval decisions, the agency said, rest on the full body of scientific evidence including clinical, immunogenicity, safety and manufacturing data.

The Trust Problem

The approval lands in an environment where public confidence in vaccines has weakened considerably.

A Politico survey conducted in March found nearly half of American adults believe the science on vaccines remains unsettled and that mandating them causes harm.

Both Offit and Hotez expect that scepticism to persist, and both attribute part of it to Kennedy’s influence. Offit described an erosion of faith in public health institutions running alongside an erosion of faith in vaccines themselves.

Hotez found something encouraging in the approval regardless. He called it a good sign, indicating that the agencies are still moving forward despite the political pressure around them.

What It Means for Patients

For adults 50 and older, a new option now exists, though access will depend heavily on where you fill prescriptions.

Anyone interested in mFlusiva this season will likely need to check with independent pharmacies or smaller chains rather than assuming the large retailers will stock it. Speaking with a doctor about whether it suits your situation is the sensible first step.